Disease Detail

ID DOID:11934
Name head and neck cancer
Definition An organ system cancer that arises in the head or neck region. This region includes the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer head and neck cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 R175H ReACp53 head and neck cancer sensitive detail...
ALK wild-type Dalantercept + Cisplatin head and neck cancer predicted - sensitive detail...
ATM loss AZD6738 + Olaparib head and neck cancer predicted - sensitive detail...
Unknown unknown Cisplatin + GL-ONC1 + Radiotherapy head and neck cancer not applicable detail...
BRAF G469A Ulixertinib head and neck cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00903461 Phase Ib/II EGFR Antisense DNA Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma Terminated
NCT00970502 Phase Ib/II Celecoxib + Erlotinib Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer Completed
NCT00978250 Phase II FdCyd + THU A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) Active, not recruiting
NCT01218048 Phase II Cisplatin Carboplatin Cetuximab ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma Completed
NCT01351103 Phase I LGK974 LGK974 + PDR001 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Active, not recruiting
NCT01588431 Phase II Cisplatin + Docetaxel + Cetuximab Bevacizumab Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer Active, not recruiting
NCT01831089 Phase I Lurbinectedin + Paclitaxel + Bevacizumab Lurbinectedin + Paclitaxel Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Completed
NCT01835626 Phase II Vismodegib Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma Recruiting
NCT01860430 Phase I Cetuximab + Ipilimumab A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer Active, not recruiting
NCT01874860 Phase I Doxycycline Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients Recruiting
NCT01935921 Phase I Cetuximab + Ipilimumab Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer Active, not recruiting
NCT01968109 Phase I Nivolumab + Relatlimab Relatlimab Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Recruiting
NCT01976741 Phase I Rogaratinib Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor Active, not recruiting
NCT02004106 Phase I RO6895882 A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors Completed
NCT02014909 Phase I CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab Cetuximab + CDX-3379 CDX-3379 + Erlotinib A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Completed
NCT02051751 Phase I BYL719 + Paclitaxel A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer Completed
NCT02107235 Phase I Cisplatin rigosertib Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer Completed
NCT02113878 Phase I BKM120 + Cisplatin Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck Active, not recruiting
NCT02318771 Phase I Pembrolizumab Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer Active, not recruiting
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Active, not recruiting
NCT02471846 Phase I GDC-0919 Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02488759 Phase Ib/II Nivolumab A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358) Recruiting
NCT02538627 Phase I Seribantumab MM-151 Phase 1 Combination Study of MM-151 and MM-121 Terminated
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated
NCT02646319 Phase II Nab-Rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Active, not recruiting
NCT02655822 Phase I Atezolizumab CPI-444 Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers Recruiting
NCT02671955 Phase I JNJ-61610588 A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated
NCT02693535 Phase II Vemurafenib + Cobimetinib Regorafenib Vismodegib Bosutinib Palbociclib Cetuximab Axitinib Pembrolizumab Temsirolimus Dasatinib Pertuzumab + Trastuzumab Crizotinib Sunitinib Olaparib Erlotinib TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer Recruiting
NCT02710396 Phase II Pembrolizumab Genetic Predictors of Benefit to Pembrolizumab Recruiting
NCT02841748 Phase II Pembrolizumab A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study Recruiting
NCT02953782 Phase Ib/II Cetuximab + Hu5F9-G4 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer Recruiting
NCT03109873 Phase I Metformin Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer Active, not recruiting
NCT03207867 Phase II PBF-509 + PDR001 A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Recruiting
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Recruiting
NCT03355560 Phase II Nivolumab Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy Recruiting